Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes.

Nikolas PlevrisGareth R JonesPhilip W JenkinsonMathew LyonsCher S ChuahLynne M MerchantRebecca J PattendenEleanor F WatsonGwo-Tzer HoColin L NobleShahida DinAlan G ShandIan D ArnottCharlie W Lees

Published in: Digestive diseases and sciences (2018)

The transition to CT-P13 from Remicade for the treatment of Crohn's disease is safe and has no negative effect on clinical outcomes at 12 months.

Keyphrases

computed tomography
image quality
dual energy
contrast enhanced
primary care
healthcare
positron emission tomography
magnetic resonance imaging
study protocol
type diabetes
metabolic syndrome
magnetic resonance
randomized controlled trial
adipose tissue
combination therapy
pet ct